Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3972307 | 0.99 | HRH3 (0.39) | HRH3HDAC4KDM4ECHRNA7GAA | |
| SCHEMBL3975123 | 0.81 | HRH3 (0.41) | HRH3CHRNA7ACHE | |
| Hydrochloric Acid SCHEMBL3972229 | 0.80 | HRH3 (0.41) | HRH3CHRNA7ALDH1A1CYP3A4RECQL | |
| Hydrochloric Acid SCHEMBL3977317 | 0.80 | HRH3 (0.41) | HRH3CHRNA7ALDH1A1CYP3A4RECQL | |
| SCHEMBL1743020 | 0.80 | HDAC4 (0.40) | HRH3HDAC4 | |
| Hydrochloric Acid SCHEMBL3971041 | 0.77 | HRH3 (0.40) | HRH3CHRNA7 | |
| SCHEMBL1743129 | 0.74 | ACVR1 (0.41) | HRH3HDAC4 | |
| SCHEMBL1744208 | 0.73 | HRH3 (0.39) | HRH3 | |
| SCHEMBL1742827 | 0.73 | HRH3 (0.39) | HRH3 | |
| SCHEMBL1742292 | 0.73 | RET (0.40) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| EP-1474401-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| WO-2003066604-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | HRH3 1/4885HDAC4 754/4885KDM4E 1574/4885 |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HRH3, HRH2, HRH4 | HRH3 1/4885HDAC4 754/4885KDM4E 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.